

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.
294-262 PCT/USSERIAL NO.
10/594,382APPLICANT
Schwartz-Albiez, et al.CONFIRMATION NO.
UnassignedFILING DATE
September 26, 2006GROUP
Unassigned

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
		DE 102 45 927 A	04/15/2004	Germany				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

			Theunissen, et al., "Long-term engrafting umbilical cord blood cells are preserved after ex vivo culture in stroma-free culture," <i>Online!</i> May 2001, http://mmserver.cjp.com/gems/blood/ABMT.10.verfaillie.pdf , pgs 599-603.
			Pankaj, et al., "Human LTC-IC can be maintained for at least 5 weeks in vitro when interleukin-3 and a single chemokine are combined with o-sulfated heparin sulfates: Requirement for optimal binding interactions of heparin sulfate with early-acting cytokines and matrix proteins," <i>Blood</i> January 2000, 95(1):147-155.
			Pankaj, et al., "Structurally specific heparin sulfates support primitive human hematopoiesis by formation of a multimolecular stem cell niche," <i>Blood</i> December 1998, 92(12):4641-4651.
			Lewis, et al., "Umbilical cord blood cells capable of engrafting in primary, secondary, and tertiary xenogeneic hosts are preserved after ex vivo culture in a noncontact system," <i>Blood</i> June 2001, 97(11):3441-3449.
			Schubert, "Einfluss regioselektiv modifizierter Heparansulfate auf den Erhalt and die Expansion primitiver hamatopoietischer Stammzelle and Vorlauferzellen," <i>Online!</i> 2004, http://doctor-schubert.de/downloads/Dissertation%20M.Schubert.pdf .

EXAMINER

/Leon Lankford Jr/

DATE CONSIDERED

06/19/2011

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 294-262 PCT/US	SERIAL NO. 10/594,382
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	APPLICANT Schwartz-Albiez, et al.	CONFIRMATION NO. Unassigned
	FILING DATE September 26, 2006	GROUP Unassigned

			Punzel, et al., "The microenvironment of AFT024 cells maintains primitive human hematopoiesis by counteracting contact mediated inhibition of proliferation." <i>Cell Communication & Adhesion</i> , May-June 2002, 9(3):149-159.
			Gupta, et al., "Artificial 'proteoglycan-like' molecules containing heparin sulfate enhance the ability of cytokines to maintain human hematopoietic stem cells in vitro," <i>Journal of Investigative Medicine</i> , 1995, 43(SUPPL2):342A.
			Moore, et al., "In vitro maintenance of highly purified, transplantable hematopoietic stem cells," <i>Blood</i> , 1997, 89(12):4337-4347.
			Moore, et al., "Hematopoietic Activity of a Stromal Cell Transmembrane Protein Containing Epidermal Growth Factor-Like Repeat Motifs," <i>Proceedings of the National Academy of Sciences of USA</i> , April 1997, 94:4011-4016.
			Stringer, et al., "Identification of an MIP-1alpha-binding heparin sulfate oligosaccharide that supports long-term in vitro maintenance of human LTC-ICs," <i>Blood</i> , March 2003, 101(6):2243-2245.

231578_1

EXAMINER	/Leon Lankford Jr/	DATE CONSIDERED	06/19/2011
----------	--------------------	-----------------	------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.L./